382 related articles for article (PubMed ID: 18075844)
21. Drospirenone--a new progestogen with antimineralocorticoid activity, resembling natural progesterone.
Oelkers W
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():17-24. PubMed ID: 11246598
[TBL] [Abstract][Full Text] [Related]
22. Prospective study evaluating olfactometric and rhinomanometric outcomes in postmenopausal women on 1 mg 17beta-estradiol and 2 mg drospirenone HT.
Caruso S; Serra A; Grillo C; De Leo V; Maiolino L; Agnello C; Cianci A
Menopause; 2008; 15(5):967-72. PubMed ID: 18551084
[TBL] [Abstract][Full Text] [Related]
23. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
Boschitsch E; Skarabis H; Wuttke W; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
[TBL] [Abstract][Full Text] [Related]
24. Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
Preston RA; White WB; Pitt B; Bakris G; Norris PM; Hanes V
Am J Hypertens; 2005 Jun; 18(6):797-804. PubMed ID: 15925739
[TBL] [Abstract][Full Text] [Related]
25. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
26. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
White WB; Pitt B; Preston RA; Hanes V
Circulation; 2005 Sep; 112(13):1979-84. PubMed ID: 16186434
[TBL] [Abstract][Full Text] [Related]
27. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
Simoncini T; Genazzani AR
Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
[TBL] [Abstract][Full Text] [Related]
28. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone.
Oelkers W
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():19-26; discussion 42-3. PubMed ID: 12659403
[TBL] [Abstract][Full Text] [Related]
29. Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms.
Ylikorkala O
Climacteric; 2005 Oct; 8 Suppl 3():1-3. PubMed ID: 16203649
[No Abstract] [Full Text] [Related]
30. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women.
Tankó LB; Christiansen C
J Intern Med; 2005 Dec; 258(6):544-53. PubMed ID: 16313478
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
[TBL] [Abstract][Full Text] [Related]
32. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
33. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
[TBL] [Abstract][Full Text] [Related]
34. Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension.
White WB
Climacteric; 2007 Feb; 10 Suppl 1():25-31. PubMed ID: 17364595
[TBL] [Abstract][Full Text] [Related]
35. Yasmin: the reason why.
Thorneycroft IH
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
[TBL] [Abstract][Full Text] [Related]
36. Effect of estradiol-drospirenone hormone treatment on myocardial perfusion reserve in postmenopausal women with angina pectoris.
Knuuti J; Kalliokoski R; Janatuinen T; Hannukainen J; Kalliokoski KK; Koskenvuo J; Lundt S
Am J Cardiol; 2007 Jun; 99(12):1648-52. PubMed ID: 17560868
[TBL] [Abstract][Full Text] [Related]
37. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg.
Johansen OE; Qvigstad E
Adv Ther; 2008 Jun; 25(6):525-51. PubMed ID: 18568306
[TBL] [Abstract][Full Text] [Related]
38. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
L'hermite M; Simoncini T; Fuller S; Genazzani AR
Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
[TBL] [Abstract][Full Text] [Related]
39. Optimizing the dose of hormone replacement therapy.
Rice VM
Int J Fertil Womens Med; 2002; 47(5):205-10. PubMed ID: 12469707
[TBL] [Abstract][Full Text] [Related]
40. Alternatives for optimal hormone replacement therapy.
Sitruk-Ware R
Climacteric; 2003 Aug; 6 Suppl 2():11-6. PubMed ID: 14669839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]